Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO

Avalyn Pharma Inc. shares jumped 44% in its trading debut, after the biopharmaceutical company raised $300 million in an upsized US initial public offering.
Source
Bloomberg Markets
Opens original article in a new tab



